Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CIMA Labs Inc.

http://www.cimalabs.com/

Latest From CIMA Labs Inc.

Opioids Need Comparative Deterrence Studies, FDA Panel Says

Review of oral, nasal and intravenous abuse-deterrence claims for Teva's long-acting hydrocodone Vantrela ER highlights the lack of head-to-head studies against approved abuse-deterrent formulations and spurs debate on relevant comparators.

BioPharmaceutical United States

Teva's Opioid Vantrela: Conflicting Data On Oral Abuse Deterrence

Human abuse liking study, in vitro data paint different pictures of potential for hydrocodone extended-release product to deter oral abuse, FDA says ahead of advisory committee review; agency finds support for abuse-deterrent claims for intranasal, intravenous use.

BioPharmaceutical United States

Deals Shaping The Medical Industry, November 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Cephalon: Can Spec Pharma do R&D?

Cephalon's 2005 dealmaking flurry illustrates the growing influence of in-house R&D on a firm whose success to date has come from in-licensing. Its challenge will be selling investors pipeline potential, as well as earnings growth.

BioPharmaceutical Strategy
See All

Company Information

UsernamePublicRestriction

Register